Literature DB >> 24916430

Mitochondrial disease: clinical aspects, molecular mechanisms, translational science, and clinical frontiers.

Ben Thornton1, Bruce Cohen2, William Copeland3, Bernard L Maria4.   

Abstract

Mitochondrial medicine provides a metabolic perspective on the pathology of conditions linked with inadequate oxidative phosphorylation. Dysfunction in the mitochondrial machinery can result in improper energy production, leading to cellular injury or even apoptosis. Clinical presentations are often subtle, so clinicians must have a high index of suspicion to make early diagnoses. Symptoms could include muscle weakness and pain, seizures, loss of motor control, decreased visual and auditory functions, metabolic acidosis, acute developmental regression, and immune system dysfunction. The 2013 Neurobiology of Disease in Children Symposium, held in conjunction with the 42nd Annual Meeting of the Child Neurology Society, aimed to (1) describe accepted clinical phenotypes of mitochondrial disease produced from various mitochondrial mutations, (2) discuss contemporary understanding of molecular mechanisms that contribute to disease pathology, (3) highlight the systemic effects produced by dysfunction within the mitochondrial machinery, and (4) introduce current strategies that are being translated from bench to bedside as potential therapeutics.
© The Author(s) 2014.

Entities:  

Keywords:  mitochondrial disease

Mesh:

Year:  2014        PMID: 24916430      PMCID: PMC4550036          DOI: 10.1177/0883073814537379

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  5 in total

1.  Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy.

Authors:  Tina D Jeppesen; Marianne Schwartz; David B Olsen; Flemming Wibrand; Thomas Krag; Morten Dunø; Simon Hauerslev; John Vissing
Journal:  Brain       Date:  2006-06-30       Impact factor: 13.501

2.  Random genetic drift determines the level of mutant mtDNA in human primary oocytes.

Authors:  D T Brown; D C Samuels; E M Michael; D M Turnbull; P F Chinnery
Journal:  Am J Hum Genet       Date:  2000-12-29       Impact factor: 11.025

3.  Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions.

Authors:  Tanja Taivassalo; Julie L Gardner; Robert W Taylor; Andrew M Schaefer; Jane Newman; Martin J Barron; Ronald G Haller; Douglass M Turnbull
Journal:  Brain       Date:  2006-11-03       Impact factor: 13.501

4.  Development of a single-chain, quasi-dimeric zinc-finger nuclease for the selective degradation of mutated human mitochondrial DNA.

Authors:  Michal Minczuk; Monika A Papworth; Jeffrey C Miller; Michael P Murphy; Aaron Klug
Journal:  Nucleic Acids Res       Date:  2008-05-29       Impact factor: 16.971

5.  Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs.

Authors:  Sandra R Bacman; Siôn L Williams; Milena Pinto; Susana Peralta; Carlos T Moraes
Journal:  Nat Med       Date:  2013-08-04       Impact factor: 53.440

  5 in total
  4 in total

Review 1.  Mitochondria-Induced Immune Response as a Trigger for Neurodegeneration: A Pathogen from Within.

Authors:  Marta Luna-Sánchez; Patrizia Bianchi; Albert Quintana
Journal:  Int J Mol Sci       Date:  2021-08-07       Impact factor: 5.923

2.  Mitochondriotropic lanthanide nanorods: implications for multimodal imaging.

Authors:  Harwinder Singh; Sreejesh Sreedharan; Esteban Oyarzabal; Tufan Singha Mahapatra; Nicola Green; Yen-Yu Ian Shih; Manasmita Das; Jim A Thomas; Sumit Kumar Pramanik; Amitava Das
Journal:  Chem Commun (Camb)       Date:  2020-06-12       Impact factor: 6.222

Review 3.  Mitochondrial Nucleoid: Shield and Switch of the Mitochondrial Genome.

Authors:  Sung Ryul Lee; Jin Han
Journal:  Oxid Med Cell Longev       Date:  2017-06-07       Impact factor: 6.543

4.  Effective and safe diet therapies for Lennox-Gastaut syndrome with mitochondrial dysfunction.

Authors:  Ji-Hoon Na; Heung-Dong Kim; Young-Mock Lee
Journal:  Ther Adv Neurol Disord       Date:  2020-02-06       Impact factor: 6.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.